Plain-English translation of NCT07072234 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase 1 trial is testing a new cell therapy called CD70 CAR NK cells that have been specially engineered in the laboratory to fight kidney cancer. These are immune cells (natural killer cells) that have been modified to recognize and attack cancer cells. The trial will determine the safest and most effective dose of this treatment for people whose kidney cancer has not responded to other therapies.
Many people with advanced kidney cancer eventually stop responding to standard treatments like immunotherapy drugs and targeted therapies, leaving them with few options. This medication uses a newer approach—engineered immune cells—that may help patients whose cancer is no longer controlled by existing treatments.
You likely qualify if…
You likely don't qualify if…
You will first have a biopsy or tissue sample taken to confirm your tumor has the CD70 protein. If you qualify, you'll receive chemotherapy to prepare your body for the new cells, followed by an infusion of the engineered immune cells. You will then be closely monitored with regular blood tests, imaging scans, and clinic visits to watch for side effects and to see whether your cancer responds to the treatment. The trial will take place over several months, with your doctors carefully tracking both your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~30 participants
Started
September 2025
Primary completion
February 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Andrew C Johns, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.